Bispecific antibody platforms for cancer immunotherapy.

Authors :: Lameris R
de Bruin RC
Schneiders FL
van Bergen en Henegouwen PM
Verheul HM
de Gruijl TD
van der Vliet HJ
Source :: Critical reviews in oncology/hematology [Crit Rev Oncol Hematol] 2014 Dec; Vol. 92 (3), pp. 153-65. Date of Electronic Publication: 2014 Aug 20.
Publication Year :: 2014
Abstract: Over the past decades advances in bioengineering and expanded insight in tumor immunology have resulted in the emergence of novel bispecific antibody (bsAb) constructs that are capable of redirecting immune effector cells to the tumor microenvironment. (Pre-) clinical studies of various bsAb constructs have shown impressive results in terms of immune effector cell retargeting, target dependent activation and the induction of anti-tumor responses. This review summarizes recent advances in the field of bsAb-therapy and limitations that were encountered. Furthermore, we will discuss potential future developments that can be expected to take the bsAb approach successfully forward.<br /> (Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.)